

☐ Tracheal aspirate ☐ Other, specify: ___

EMERGING INFECTIONS PROGRAM PULMONARY NONTUBERCULOUS MYCOBACTERIA (NTM) SURVEILLANCE CASE REPORT FORM - 2025

		(N1M) S	UKVEILLA	NCE CA	SE REPORT	FORM -	2025			
Patient's Na	ame:	Ph	Phone no. ()							
Address:					MRN:					
City:	State: ZIP:).	Facility:					
o.i.y.						,				
		-PATIENT IDEN	TIFIER INFORM	MATION IS	NOT TRANSMITTI	ED TO CDC]-			
. STATE:	2. COUNTY:	3. STATE ID:	4. PATIENT	ID:	5. LABORATORY ID WHERI NTM INITIALLY IDENTIFIED			6. PROVIDER ID W INDEX SPECIMEN		
	-		-				=			
7. DATE OF E	BIRTH:	8. AGE:		1	9. SEX:					
		<u> </u>	/s ☐ Mos. ☐] Yrs	☐ Male ☐ Fe	male ∐ N	/lissing	value		
	D/OR ETHNICITY: (Che						_	7		
_	ndian or Alaska Native	☐ Black or African Am			tern or North Africa			☐ White		
□ Asian		☐ Hispanic or Latino		Native Haw	aiian or Other Pa	cific Islande	er L	Unknown		
11. WEIGHT:		12. HEIGHT:			(record only if h					
lbs	soz. OR	ft	_ in. OR	or weigr	nt is not available	∌)	SPE	CIMEN COLLECTION	N (DISC):	
kg	☐ Unknown	cm 🗆 U	Jnknown		_ Unknown				☐ Unknown	
5. LOCATION	OF EXTRAPULMONAL	RY INDEX SPECIMEN CO	OLLECTION:					RY INDEX SPECIMEN	COLLECTION SITE	
		☐ INPATIENT:		-		(Check all that apply): ☐ BAL				
		Facility ID:		cility ID:			ng tissu	e		
☐ Emerge	ency room octor's office			-		☐ Sputum (expectorated or induced)				
☐ Dialysis		□ OR □ Radiology	Fac □ Au :	cility ID:		☐ Tracheal aspirate				
☐ Surgery		☐ Other inpatient				☐ Other lower respiratory site (specify):				
	ational/Clinical decision ι	·		known						
☐ Other o	utpatient					16a. Coll	lected f	f or: □ TB evaluation	☐ CF follow-up	
	7					☐ Oti	her/ not	documented		
6b. ☐ Index specimen(s) detected solely via multiplex/NGS lab-developed test?						17 FINA	I RESI	JLT DATE: -	_	
	. , ,	EXTRAPULMONARY IN	<u>.</u>			17.11117	LICE	JEI DATE.		
_			-M. avium con		AC)		N - 4 '	TD	al formula are (NITD)	
	complex (MAC)				•		⊔ NOt	TB, not characterize	a turtner (N1B)	
☐ M. aviu	` '	_	<i>Л. abscessus</i> co		•					
	cellulare subsp. chimaera	(-)	∃ M. abscessu	•						
	ncellulare subsp. intracellu] M. abscessu							
☐ Other N	MAC, specify:		☐ M. abscessu	'						
☐ MAC, n	ot otherwise specified (M	,			lentification not pe	erformed				
		-	Λ. chelonae cor	. `	•					
		-	Λ. fortuitum cor		,					
			A. kansasii con		١)					
			Л. marinum (Мл		410					
					(NC)TH)				
			lon-MAC, not c							
9. CLINICIAN	N-DIAGNOSED PULMON	NARY NTM DISEASE?	☐ Yes [□ No □	Unknown 19	a. ∐ Con	itamina	tion or colonization s	uspected	
0. WERE MIC	CROBIOLOGICAL TEST	S OF PULMONARY SPE	CIMENS POSI	TIVE FOR	NTM IN THE 12 N	MONTHS E	BEFORE	ETHE DISC?		
☐ No microbio	ological tests, and NO me	edical record documentation	n that infection	was prese	ent →INCIDENT C	ASE				
☐ No microbio	ological tests, but medical	record documentation inc	licates infection	WAS PRI	ESENT →PREVA	LENT CAS	SE .			
□ Yes →PRE	VALENT CASE (comple	ete table below)								
Unknown										
F YES, INDIC		OF COLLECTION, AND	_	Dot- "		5 •		D-4- 40	Crasia-	
¬ • • ·	ם	ate #1 Sp	ecies	Date #	٤ (Species		Date #3	Species	
」BAL		-								
☐ Lung tissue		<u> </u>								
☐ Sputum	_	-								

21. USING THE INFORMATION IN Q DISC (Check all that apply):	21. USING THE INFORMATION IN QUESTIONS 16 AND 20, INDICATE WHICH PULMONARY NTM CRITERIA WERE MET AS OF THE DISC (Check all that apply):						
 □ A. NTM identified from microbiological testing (culture or culture independent diagnostic test [CIDT]) of ≥1 BAL or bronchial wash specimen or lung tissue specimen—CONFIRMED CASE 							
☐ B. NTM identified from microbiolog	gical testing	g (culture or CIDT) of	≥2 sputum s _l	pecimens or tracheal aspirates—CONFIRM	MED CASE		
☐ C. Lung biopsy specimen with histo NTM identified from microbiological	topathologi al testing (c	ic features (granulom culture or CIDT) of ≥1	atous inflamı pulmonary s	mation or acid-fast bacilli) PLUS pecimen— CONFIRMED CASE			
☐ D. NTM identified from microbiolog	gical testing	g (culture or CIDT) of	1 sputum spe	ecimen or tracheal aspirate only—POSSIB	LE CASE		
If CONFIRM	MED CASE	E, complete CRF. If F	POSSIBLE C	CASE, then pulmonary NTM criteria are	NOT YET MET		
22. WERE EITHER E OR F (BELOW)) REPORT	ED IN THE 12 MONT	HS AFTER	THE DISC?			
☐ Not applicable—already a confirme	ed case						
☐ E. Lung biopsy specimen with myconate of collection	cobacterial	histopathologic featu	res (granulor	natous inflammation or acid-fast bacilli)—(CONFIRMED CASE, complete CRF		
☐ F. NTM identified from microbiolog Date of collection	•	-, ,	•	y specimen other than index specimen—C —	ONFIRMED CASE, complete CRF		
Site: ☐ BAL ☐ Lung tissue	e 🗆 Spu	utum (expectorated or	rinduced)	☐ Tracheal aspirate ☐ Other lower re	spiratory site (specify):		
☐ Specimen(s) detected solely	y via multip	olex/NGS lab-develop	ed test?				
☐ No→STOP ABSTRACTION ☐ L	Unknown-	STOP ABSTRACTION	ON				
		Comple	te CRF for C	CONFIRMED CASES			
23. NTM ANTIMICROBIAL SUSCEPT	TIBILITY T	TEST (AST) RESULT	S: □ None	□ Unknown			
LABORATORY ID WHERE AST TES	STING PE	RFORMED:		<u></u>			
NTM SPECIES:	DATE OF	F COLLECTION:					
NON-MOLECULAR METHODS:							
Antimicrobial To	Test metho	od		If BMD enter MIC (mg/ml)	Interpretation		
	□BMD [□DD □ADE □Oth	□Unk	or □Unk	□S □I □R □Unknown		
1	□BMD [□DD □ADE □Oth	□Unk	or □Unk	□S □I □R □Unknown		
I	□BMD [□DD □ADE □Oth	□Unk	or □Unk	□S □I □R □Unknown		
I	□BMD [□DD □ADE □Oth	□Unk	or □Unk	□S □I □R □Unknown		
I	□BMD [□DD □ADE □Oth	□Unk	or □Unk	□S □I □R □Unknown		
I	□BMD [□DD □ADE □Oth	□Unk	or □Unk	□S □I □R □Unknown		
I	□BMD [□DD □ADE □Oth	□Unk	or □Unk	□S □I □R □Unknown		
I	□BMD [□DD □ADE □Oth	□Unk	or □Unk	□S □I □R □Unknown		
!	□BMD [□DD □ADE □Oth	\square Unk	or □Unk	□S □I □R □Unknown		
	□BMD [□DD □ADE □Oth	\square Unk	or □Unk	□S □I □R □Unknown		
	□BMD [□DD □ADE □Oth	\square Unk	or □Unk	□S □I □R □Unknown		
I	□BMD [□DD □ADE □Oth	□Unk	or □Unk	□S □I □R □Unknown		
1	□BMD [□DD □ADE □Oth	□Unk	or □Unk	□S □I □R □Unknown		
1	□BMD [□DD □ADE □Oth	□Unk	or □Unk	□S □I □R □Unknown		
1	□BMD [□DD □ADE □Oth	□Unk	or □Unk	□S □I □R □Unknown		
1	□BMD [□DD □ADE □Oth	□Unk	or □Unk	□S □I □R □Unknown		
1	□BMD [□DD □ADE □Oth	□Unk	or □Unk	□S □I □R □Unknown		
	□BMD [□DD □ADE □Oth	□Unk	or \square Unk	□S □I □R □Unknown		
!	□BMD [□DD □ADE □Oth	□Unk	or □Unk	□S □I □R □Unknown		
!	□BMD [□DD □ADE □Oth	□Unk	or □Unk	□S □I □R □Unknown		
	□BMD [□DD □ADE □Oth	□Unk	or □Unk	□S □I □R □Unknown		
1	□BMD [□DD □ADE □Oth	□Unk	or \square Unk	□S □I □R □Unknown		

MOLECULAR METHODS:						
Gene name	Test method	Result		Interpretation		
□ erm □ rpoB □ rrl □ rrs □ Other, specify:	☐ Line Probe ☐ PCR ☐ Sanger Sequencing ☐ Other, specify:	☐ Gene absent ☐ Indeterminate ☐ Mutations/variants, specify: ☐ Other abnormal result, spec ☐ No abnormal results ☐ Unknown	ify:	□ Suggests resistance/ Resistance is predicted □ Suggests susceptibility/ Resistance not predicted □ Other interpretation, specify: □ Unknown		
□ erm □ rpoB □ rf □ rrs □ Other, specify: □ erm □ rpoB	☐ Line Probe ☐ PCR ☐ Sanger Sequencing ☐ Other, specify: ☐ Line Probe ☐ PCR	☐ Gene absent ☐ Indeterminate ☐ Mutations/variants, specify: ☐ Other abnormal result, specify: ☐ No abnormal results ☐ Unknown ☐ Gene absent ☐ Indeterminate	ify:	□ Suggests resistance/ Resistance is predicted □ Suggests susceptibility/ Resistance not predicted □ Other interpretation, specify: □ Unknown □ Suggests resistance/ Resistance is predicted □ Suggests susceptibility/ Resistance not predicted		
☐ <i>rrl</i> ☐ <i>rrs</i> ☐ Other, specify:	☐ Sanger Sequencing ☐ Other, specify:	□ Mutations/variants, specify: □ Other abnormal result, spec □ No abnormal results □ Unknown		□ Unknown	retation, specify:	
☐ erm ☐ rpoB ☐ rf ☐ rrs ☐ Other, specify:	☐ Line Probe ☐ PCR ☐ Sanger Sequencing ☐ Other, specify:	☐ Gene absent ☐ Indeterminate ☐ Mutations/variants, specify: ☐ Other abnormal result, spec ☐ No abnormal results ☐ Unknown	ify:	□ Suggests resistance/ Resistance is predicted □ Suggests susceptibility/ Resistance not predicted □ Other interpretation, specify: □ Unknown		
☐ erm ☐ rpoB ☐ rrl ☐ rrs ☐ Other, specify:	☐ Line Probe ☐ PCR ☐ Sanger Sequencing ☐ Other, specify:	☐ Gene absent ☐ Indeterminate ☐ Mutations/variants, specify: ☐ Other abnormal result, spec ☐ No abnormal results ☐ Unknown	ify:	 ☐ Suggests resistance/ Resistance is predicted ☐ Suggests susceptibility/ Resistance not predicted ☐ Other interpretation, specify: ☐ Unknown 		
24. NTM SIGNS & SYMPT	OMS IN THE 90 DAYS BEFOR	RETHE DISC (Check all that app	ly): ☐ None ☐ L	Jnknown \square P	revalent case, no symptoms found	
☐ Chest Pain	☐ Dyspnea/Shortness of brea	ath Hemoptysis	☐ Weight	loss		
☐ Chills	☐ Fatigue or malaise	☐ Night sweats	☐ Wheez	ing		
☐ Cough	☐ Fever	\square Sputum production	☐ Other,	specify:		
25. IMMUNOSUPPRESSIV	/E MEDICATION IN THE 90 D	AYS BEFORE THE DISC (Check	(all that apply): [☐ None of the b	elow 🗆 Unknown	
☐ Abatacept/Orencia	☐ Cyclophosphamide	e ☐ IL-23 blocker	☐ Other	chemotherapy	☐ Steroid, inhaled	
☐ Azathioprine	☐ Deucravacitinib	☐ JAK inhibitor ☐ S1Pl		R modulator		
☐ B Cell depletion agent	☐ IL-6 blocker	☐ Mycophenolate	☐ Stero	id, IV, IM, or oral	\square TNF- α inhibitor	
☐ Checkpoint inhibitor	☐ IL-17 inhibitor					
26. HOSPITALIZATION(S)	IN THE 12 MONTHS BEFORE	TO 30 DAYS AFTER THE DISC	: 🗆 Yes 🗆 No 🗀 🛚	Unknown	27. LAST KNOWN STATUS WITHIN	
Admission date	Discharge	on?	180 DAYS OF THE DISC:			
[_		☐ Yes ☐ No ☐ U	Jnknown	☐ Alive ☐ Died	
[☐ Unknown -	- 🗆 Unknown	☐ Yes ☐ No ☐ U	Jnknown	□ Unknown	
		· 	□ Yes □ No □ U		Date of last known status:	
			□ Yes □ No □ U			
	☐ Unknown		□ Yes □ No □ U			

28. DID PATIENT RECEIVE CARE FROM OR WERE THEY REFERRED TO A SPECIALIST FOR NTM EVALUATION OR MANAGEMENT WITHIN 12 MONTHS BEFORE TO 90 DAYS AFTER THE INDEX SPECIMEN RESULT DATE? (Check all that apply):								28a. WERE ANY REFERRALS WITHIN 12 MONTHS BEFORE TO 30 DAYS AFTER THE INDEX	
1, 2,		ulmona	ry specialist	☐ Surgeon				ECIMEN RESULT DATE?	
☐ Other, specify: ☐ No		lone	one				☐ Yes ☐ No ☐ Unknown		
28b. DID THE PATIENT UNDERGO SURGERY TO MANAGE NTM INFECTION ON THE DISC THROUGH 180 DAYS AFTER THE INDEX SPECIMEN RESULT DATE? □ Yes; specify type of surgery:								29. INFECTION TYPE ☐ Disseminated ☐ Not disseminated	
□ No □ Unknown									
□ NO □ Unknown								Jnknown	
30. UNDERLYING CONDITIONS (Check a Chronic Lung Disease	,		ne Unknowr ed Condition	n Malignancy	,		Rena	al Disease	
☐ Cystic fibrosis	☐ HIV infecti	ion		☐ Malignar	ncy, hematologic		☐ Cl	hronic kidney disease	
☐ Chronic pulmonary disease	☐ AIDS/	CD4 co	unt <200	☐ Malignar	ncy, solid organ (noi	n-metastatic)) [Lowest serum creatinine:	
Chronic Metabolic Disease	☐ Primary in	nmunod	eficiency	☐ Malignar	ncy, solid organ (me	tastatic)	_	mg/dL	
☐ Diabetes mellitus	☐ Transplan	ıt, hema	topoietic stem cell	Neurologic	Condition] Unknown or not done	
☐ With chronic complications	☐ Transplar	nt, solid	organ	☐ Cerebra	l palsy		Skin	Condition	
Cardiovascular Disease	(specify):	·		☐ Chronic	cognitive deficit		□ВІ	istering disease	
☐ CVA/Stroke/TIA	Liver Diseas	e		□ Dementi	а		□Вι	□ Burn	
☐ Congenital heart disease	☐ Chronic liver disease			☐ Epilepsy/seizure/seizure disorder			☐ Decubitus/pressure ulcer		
☐ Congestive heart failure	☐ Ascites			☐ Multiple sclerosis			☐ Eczema		
☐ Myocardial infarction	☐ Cirrhosis			☐ Neuropathy			☐ Ps	soriasis	
☐ Peripheral vascular disease (PVD)	☐ Hepatic encephalopathy			☐ Paresis			□ St	☐ Surgical wound	
Gastrointestinal Disease	☐ Variceal bleeding			☐ Parkinson's disease			☐ Ot	ther chronic ulcer or chronic wound	
☐ Diverticular disease	☐ Hepatitis C			☐ Spinal co	ord injury		Othe	r	
☐ Inflammatory bowel disease	\square Treated, in SVR			Plegias/Paralysis			☐ Co	onnective tissue disease	
☐ Peptic ulcer disease	☐ Peptic ulcer disease ☐ Current, chronic		ic	☐ Hemiplegia				besity or morbid obesity	
☐ Short gut syndrome			☐ Paraplegia				☐ Pr	regnant	
				☐ Quadripl	egia				
31. OTHER UNDERLYING CONDITIONS	(Check all the	at apply): None Unl	known					
☐ Bronchiectasis		GERD)		☐ Pulmonary su	ırgical proce	dure	☐ Rheumatoid arthritis	
☐ Chest wall deformity (e.g., pectus excava	atum) 🗆	Histor	y of tuberculosis	Specify surgery:				□ Scoliosis	
□ COPD		Lung	cancer / History of I	of lung cancer					
☐ Cough suppression disorder		Mitral	valve prolapse	Date of surgery:					
☐ Emphysema					☐ Unknown				
32. SUBSTANCE USE			HISTORY OF SI	MOKING (Ch	eck all that apply):			ALCOHOL ABUSE:	
ONOUGHO (Objects of the first or or halo			☐ None documented ☐ Unknown				☐ Yes		
☐ None documented ☐ Unknown			☐ Tobacco ☐ E-nicotine delivery system ☐ Marijuana			rijuana		☐ None documented	
☐ Tobacco ☐ E-nicotine delivery system ☐ Marijuana						□ Unknown			
33. WAS THE PATIENT HOMELESS IN 1	THE YEAR	33a. C	VERNIGHT STAY	TAY IN LTCF IN THE YEAR 33b. WA			S THE PATIENT IN 5		
BEFORE THE DISC?		BEFO	RE THE DISC?	THE DISC? 7 CFF97			7H=CB5@CF`89H9BH=CB`:57=@HM		
☐ Yes ☐ No ☐ Unknown		☐ Yes ☐ No ☐ Unknown IN THI				THE YEAR BEFORE THE DISC?			
	IF YES, FACILITY ID:					☐ No ☐ Unknown			

34. CHEST IMAGING Chest imaging 90 days before to DISC (Check all that apply): Chest CT scan No Chest x-ray Un 35. DID THE PATIENT HAVE A PTEST(S) FOR SARS-CoV-2 (MOL ASSAY, ANTIGEN, OR OTHER VIEXCLUDING SEROLOGY) IN THE BEFORE OR DAY OF THE DISC OF THE D	place with the DISC Yes No Unk SPECIM FIRST	SPECIMEN COLLECTION DATES FOR P		34b. If chest CT scan and/or chest x-ray, chest imaging findings (Check all that apply): None Unknown Bronchiectasis Nodular opacities Cavity or cavitation Nodules Consolidation Tree-in-bud Infiltrate POSITIVE TESTS IN THE 90 DAYS BEFORE OR DAY OF DISC: OR Date unknown OR Date unknown			
36. WAS CASE FIRST IDENTIFIED THROUGH AUDIT? Yes No Unknown 41. COMMENTS:	O 37. CRF ST. ☐ Complete ☐ Pending ☐ Chart una after 3 re	vailable	38. WAS THIS PATIENT PREVIOUSLY REPORTED TO HAIC NTM SURVEILLANCE? Yes No Unknown IF YES, PREVIOUS (1ST) STATEID:		39. DATE OF AE		40. SO INITIALS:

NTM ANTIMICROBIAL SUSCEPTIBILITY TEST (AST) RESULTS: None Unknown								
LABORATORY ID WHER		D: ECTION:						
NON-MOLECULAR METH			_					
Antimicrobial	Test method		If BMD enter MIC (mg/ml) Interpretation				
Antimicrobiai		 □ADE □Oth □Unk	or □Ui	<u> </u>				
		□ADE □Oth □Unk	or □Ui					
		□ADE □Oth □Unk	or □Ui					
		□ADE □Oth □Unk	or □Ui					
		□ADE □Oth □Unk	or □Ui					
		□ADE □Oth □Unk	or □Ui					
		□ADE □Oth □Unk	or □Ui					
		□ADE □Oth □Unk	or \square U					
		□ADE □Oth □Unk	or \square U					
		□ADE □Oth □Unk	or \square U					
		□ADE □Oth □Unk	or \square U					
		□ADE □Oth □Unk	or \square U					
	□BMD □DD [□ADE □Oth □Unk	or \square U	nk □S □I □R □Unknown				
	□BMD □DD [□ADE □Oth □Unk	or \square U	nk □S □I □R □Unknown				
	BMD □DD [□ADE □Oth □Unk	or \square U	nk □S □I □R □Unknown				
	BMD □DD [□ADE □Oth □Unk	or \square U	nk □S □I □R □Unknown				
	□BMD □DD [□ADE □Oth □Unk	or \square U	nk □S □I □R □Unknown				
	□BMD □DD [□ADE □Oth □Unk	or □U	nk □S □I □R □Unknown				
	□BMD □DD [□ADE □Oth □Unk	or \Box U	nk □S □I □R □Unknown				
	BMD □DD [□ADE □Oth □Unk	or □U	nk □S □I □R □Unknown				
	□BMD □DD [□ADE □Oth □Unk	or \Box U	nk □S □I □R □Unknown				
	□BMD □DD [□ADE □Oth □Unk	or □U	nk □S □I □R □Unknown				
MOLECULAR METHODS:								
Gene name	Test method	If Lin	e Probe or PCR, Interpreta	If Sanger Sequencing or Other, Interpretation				
□ erm	☐ Line Probe	☐ Indeterminate		Suggests resistance/ Resistance is predicted				
│ □ rpoB │ □ rrl	☐ PCR	☐ Mutations/variants, specif☐ Other abnormal result, specif	•	☐ Suggests susceptibility/ Resistance not predicted ☐ Other interpretation, specify:				
□ rrs	☐ Sanger Sequencing ☐ Other,	☐ No abnormal results	-	Unknown				
☐ Other,	specify:	☐ Unknown						
specify:	☐ Gene absent							
□ erm	☐ Line Probe	☐ Indeterminate		Suggests resistance/ Resistance is predicted				
│ □ rpoB │ □ rrl	□ PCR	☐ Mutations/variants, specif☐ Other abnormal result, specif		☐ Suggests susceptibility/ Resistance not predicted☐ Other interpretation, specify:				
□ rrs	☐ Sanger Sequencing☐ Other,	☐ No abnormal results	-	Unknown				
☐ Other,	specify:	☐ Unknown						
specify:	☐ Gene absent							
□ erm	☐ Line Probe	☐ Indeterminate		Suggests resistance/ Resistance is predicted				
☐ rpoB	□ PCR	☐ Mutations/variants, specif		☐ Suggests susceptibility/ Resistance not predicted				
\square rrl \square rrs	☐ Sanger Sequencing	☐ Other abnormal result, sp.☐ No abnormal results		Other interpretation, specify:				
☐ Other,	☐ Other,	☐ Unknown		Unknown				
specify:	specify:	Olikilowii						
İ	☐ Gene absent	İ						

EIP PULMONARY NTM CRF Page 7 of 7 □ erm □ Indeterminate ☐ Suggests resistance/ Resistance is predicted ☐ Line Probe ☐ Mutations/variants, specify:_ □ rpoB ☐ Suggests susceptibility/ Resistance not predicted ☐ PCR \square rrl ☐ Other abnormal result, specify:_ ☐ Other interpretation, specify: __ ☐ Sanger Sequencing □ rrs □ No abnormal results ☐ Unknown ☐ Other, ☐ Other, ☐ Unknown specify: specify: ☐ Gene absent \square erm □ Indeterminate ☐ Suggests resistance/ Resistance is predicted ☐ Line Probe ☐ Mutations/variants, specify: □ rpoB ☐ Suggests susceptibility/ Resistance not predicted ☐ PCR \square rrl ☐ Other abnormal result, specify:_ ☐ Other interpretation, specify: ___ ☐ Sanger Sequencing \square rrs ☐ No abnormal results ☐ Unknown ☐ Other, \square Other, ☐ Unknown specify: specify: _ ☐ Gene absent ADDITIONAL CULTURES (Please enter in chronological order) **Specimen Collection Date** Source **Species** ☐ Detected solely via multiplex/NGS lab-developed test ☐ Detected solely via multiplex/NGS lab-developed test ☐ Detected solely via multiplex/NGS lab-developed test ☐ Detected solely via multiplex/NGS lab-developed test ☐ Detected solely via multiplex/NGS lab-developed test ☐ Detected solely via multiplex/NGS lab-developed test ☐ Detected solely via multiplex/NGS lab-developed test ☐ Detected solely via multiplex/NGS lab-developed test ☐ Detected solely via multiplex/NGS lab-developed test ☐ Detected solely via multiplex/NGS lab-developed test ☐ Detected solely via multiplex/NGS lab-developed test ☐ Detected solely via multiplex/NGS lab-developed test ☐ Detected solely via multiplex/NGS lab-developed test ☐ Detected solely via multiplex/NGS lab-developed test ☐ Detected solely via multiplex/NGS lab-developed test

□ Detected solely via multiplex/NGS lab-developed test
 □ Detected solely via multiplex/NGS lab-developed test
 □ Detected solely via multiplex/NGS lab-developed test
 □ Detected solely via multiplex/NGS lab-developed test
 □ Detected solely via multiplex/NGS lab-developed test
 □ Detected solely via multiplex/NGS lab-developed test
 □ Detected solely via multiplex/NGS lab-developed test
 □ Detected solely via multiplex/NGS lab-developed test
 □ Detected solely via multiplex/NGS lab-developed test
 □ Detected solely via multiplex/NGS lab-developed test
 □ Detected solely via multiplex/NGS lab-developed test
 □ Detected solely via multiplex/NGS lab-developed test